Androgen receptor-mediated upregulation of quaking affects androgen receptor-related prostate cancer development and anti-androgen receptor therapy

被引：5

作者：

Zhang, Keke ^{[1
]}

Yan, Fei ^{[1
]}

Lei, Xiaoying ^{[2
]}

Wei, Di ^{[1
]}

Lu, Huanyu ^{[2
]}

Zhu, Zheng ^{[1
]}

Xiang, An ^{[2
]}

Ye, Zichen ^{[2
]}

Wang, Li ^{[2
]}

Zheng, Wanxiang ^{[1
]}

Li, Xi'an ^{[1
]}

Yuan, Jiarui ^{[3
]}

Lu, Zifan ^{[2
]}

Yuan, Jianlin ^{[1
]}

机构：

[1] Fourth Mil Med Univ, Xijing Hosp, Dept Urol, 15 Changle Xi Rd, Xian 710032, Shaanxi, Peoples R China

[2] Fourth Mil Med Univ, Sch Pharm, Dept Pharmacogen, State Key Lab Canc Biol, 169 Changle Xi Rd, Xian 710032, Shaanxi, Peoples R China

[3] Univ Washington, Dept Biochem, Seattle, WA 98195 USA

来源：

MOLECULAR MEDICINE REPORTS | 2018年 / 17卷 / 06期

基金：

美国国家科学基金会;

关键词：

androgen receptor; prostate-specific antigen; quaking; prostate cancer; drug sensitive; EXPRESSION; RNA; QKI; RESISTANCE; CARCINOMA; VARIANT; HSP90;

D O I：

10.3892/mmr.2018.8882

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The androgen receptor (AR) has a crucial role in prostate cancer. RNA-binding protein-mediated post-transcriptional regulation is important in the initiation and development of cancer. The present study attempted to elucidate the mutual association of AR and RNA-binding protein quaking (QKI) in the development of prostate cancer. Dual-luciferase reporter demonstrated that AR can positively regulate the expression of QKI in prostate cancer cell lines due to its effective transcription regulating function. In addition, QKI may increase expression of AR by heat shock protein 90, which is a coactivator of AR, and silencing QKI can increase the sensitive of Casodex, which is an antagonist of AR in castration-resistant prostate cancer. This may be a new strategy for advanced prostate cancer.

引用

页码：8203 / 8211

页数：9

共 50 条

[1] Androgen Receptor-Mediated Transcription in Prostate Cancer
Ozturan, Dogancan
Morova, Tunc
Lack, Nathan A.
[J]. CELLS, 2022, 11 (05)
[2] A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy
Gregory, CW
He, B
Johnson, RT
Ford, OH
Mohler, JL
French, FS
Wilson, EM
[J]. CANCER RESEARCH, 2001, 61 (11) : 4315 - 4319
[3] Intermittent anti-androgen monotherapy: a possible treatment for androgen receptor-overexpressing prostate cancer
Oliver, Tim
Berney, Dan
Shaw, Greg
[J]. CANCER RESEARCH, 2015, 75
[4] Ectopic expression of the amino-terminal peptide of androgen receptor leads to androgen receptor dysfunction and inhibition of androgen receptor-mediated prostate cancer growth
Minamiguchi, K
Kawada, M
Ohba, S
Takamoto, K
Ishizuka, M
[J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2004, 214 (1-2) : 175 - 187
[5] Androgen receptor-mediated apoptosis is regulated by photoactivatable androgen receptor ligands
Risek, Boris
Bilski, Piotr
Rice, Annette B.
Schrader, William T.
[J]. MOLECULAR ENDOCRINOLOGY, 2008, 22 (09) : 2099 - 2115
[6] Androgen receptor and prostate cancer therapy
Carvalho, H. F.
[J]. BIOPHYSICAL REVIEWS, 2021, 13 (06) : 1525 - 1526
[7] Anti-Androgen Receptor Therapies in Prostate Cancer: A Brief Update and Perspective
Huang, Jian
Lin, Biyun
Li, Benyi
[J]. FRONTIERS IN ONCOLOGY, 2022, 12
[8] The androgen/androgen receptor axis in prostate cancer
Bluemn, Eric G.
Nelson, Peter S.
[J]. CURRENT OPINION IN ONCOLOGY, 2012, 24 (03) : 251 - 257
[9] Upregulation of the androgen receptor during prostate cancer progression
Singh, A
Figg, WD
[J]. CANCER BIOLOGY & THERAPY, 2004, 3 (03) : 284 - 285
[10] Androgen receptor mediated growth of prostate (cancer)
Schalken, J
[J]. EUROPEAN UROLOGY SUPPLEMENTS, 2005, 4 (08) : 4 - 11

← 1 2 3 4 5 →